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Signal transduction by the growth hormone receptor
(GHR) occurs through growth hormone (GH)-induced
dimerization of two GHRs to form a trimeric complex. It
is thought that dimerization alone is sufficient for sig-
naling, since monoclonal antibodies (mAbs) against the
extracellular domain of the GHR elicit proliferation of
FDC-P1 cells transfected with a chimeric receptor com-
prising the extracellular domain of the GHR and the
fibronectin and cytoplasmic domains of the murine
granulocyte colony-stimulating factor receptor. We
have screened 14 GHR mAbs for proliferative activity
against characterized FDC-P1 and BaF-B03 cell lines
stably expressing the full-length human, rabbit, or rat
GHR, or the chimeric human GHR/granulocyte colony-
stimulating factor receptor, and for transactivation of
the c-fos promoter and STAT activation. With the chi-
meric receptor, eight mAbs were able to elicit prolifer-
ation, although there was no correlation between inhi-
bition of hormone binding and agonist activity. In
contrast, no mAbs were able to act as agonists with the
full-length GHR FDC-P1 cell lines, although nine com-
peted with GH for binding. A weak proliferative response
was observed in the BaF-B03 cell lines with two of the
mAbs (263 and 1C9), and the addition of anti-mouse F(ab)2
resulted in increased signaling in the hGHR BaF-B03 cell
line to a plateau of 28 6 4% of the GH maximum for mAb
263. These data could indicate considerable stringency in
the ability of mAbs to correctly dimerize the full-length
GHR. However, the ability of mAb 263 to stimulate a mu-
tant hGHR altered in the F*–G* loop of domain 2 was
nearly abolished, concurrent with an increased affinity of
this mAb for the receptor. Since the F*–G* loop undergoes
a conformational change on GH binding and is necessary
for full proliferative signaling, we propose that in addi-
tion to promoting receptor dimerization, mAb 263 may
induce specific changes in receptor conformation similar
to GH, which are required for the biological response.
Growth hormone (GH)1 regulates a wide range of processes
including somatic growth, metabolism, and synthesis of specific
proteins (1). It does this by triggering multiple second messen-
ger pathways in response to ligand binding to the GHR. The
first signaling step after ligand binding is thought to be hor-
mone-induced dimerization of identical receptor subunits. It
has been shown that formation of the trimeric complex
(GHz(GHR)2) is a sequential process involving the binding of
the hormone, first to receptor 1 and then to receptor 2, on
opposite sides of the four-a-helical bundle hormone. Receptor
binding sites on the hormone are referred to as sites 1 and 2,
respectively (2, 3). Evidence supporting a role for hormone-
induced dimerization in signaling was first provided by Fuh et
al. (4) using a cell line expressing the extracellular binding
domain of the GHR fused to the extracellular fibronectin and
cytoplasmic domains of the murine granulocyte colony-stimu-
lating factor (mG-CSF) receptor. These workers reported that a
hGH analogue mutated in binding site 2 was unable to trans-
mit a proliferative signal because it was unable to induce
dimerization. Similarly, our mutagenic analysis of the dimer-
ization domain that links dimerized receptors in the trimeric
complex, demonstrates that receptor dimerization is necessary
for signal transduction (5). The question arises, however, as to
whether dimerization alone is sufficient, or whether there are
additional hormone-induced conformational changes in the re-
ceptor required for signaling. The study of Fuh et al. (4) showed
that three mAbs raised against the GHR could elicit cell pro-
liferation in FDC-P1 myeloid cells containing the chimeric
hGHR/G-CSF receptor, presumably by cross-linking two recep-
tors in the same manner as GH (2, 3). Accordingly, monovalent
Fab fragments of these mAbs were incapable of eliciting a
biological response. This supports the notion that receptors are
easily activated by cross-linking and that the constraints for
signaling are minimal.
Because Fuh et al. (4) utilized the chimeric hGHR/G-CSF
receptor in their study, it is not clear whether these mAbs can
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activate the full-length GHR or whether the ability of these
cells to respond to the GHR mAbs is in fact characteristic of
G-CSF signaling. This is relevant, because we have previously
been unable to find agonist activity of one of the mAbs used in
this study (mAb 263) in a system measuring the insulin-like
actions of GH (6). We have also found that a region of the
extracellular domain of the GHR that undergoes a conforma-
tional change upon hormone binding (as visualized in the crys-
tal structure) is an important determinant for proliferative
signaling in FDC-P1 cells (7). This region, the F9–G9 loop in
domain 2 of the GHR, is displaced in site 1 of the GHR but not
in site 2, presumably as a result of the close interaction with
the hormone at site 1 but not at site 2 (8). Modification of this
loop has little affect on the ability of GH to form the trimeric
GHz(GHR)2 complex, but the ability of this receptor to activate
a maximum proliferative response in FDC-P1 cells expressing
this receptor is markedly attenuated (7). This observation sug-
gests that activation of the GHR requires more than simple
dimerization and that specific conformational changes in the
GHR take place that are necessary for effective signaling. To
further test this hypothesis, we have examined here the ability
of 14 mAbs directed to the extracellular domain of the GHR to
induce a biological response in the same cell line used by Fuh
et al. (4) (hGHR/mG-CSF receptor) and in FDC-P1 and BaF-
B03 cells expressing the full-length human, rabbit, and rat
GHRs. We conclude that it is possible for mAbs raised against
the extracellular domain of the GHR to initiate a biological
response through dimerization of two GHRs. However, since
only 2 of 14 mAbs were able to signal through the full-length
receptor, and the response was not of the same magnitude as
GH alone, we propose that a full biological response through
the GHR is dependent on specific hormone-induced conforma-
tional change(s).
MATERIALS AND METHODS
Establishment and Characterization of Cell Lines Expressing the
Human, Rabbit, and Rat Growth Hormone Receptors and the Chimeric
hGHR/mG-CSF Receptor—FDC-P1 cells containing the chimeric
hGHR/mG-CSF receptor (HC-2 cells) as used in Refs. 4 and 9 were a gift
from Prof. S. Nagata (Osaka Biosciences Institute, Japan). The FDC-P1
cells expressing the rabbit GHR (FDC-P1-RGHR3B cells) are described
in Ref. 8. A clone expressing the full-length human GHR (FDC-P1-
HGHRD11 cells) was produced and characterized in the same manner
described in Ref. 10, using the hGHR cDNA in the PECE expression
vector (generously provided by Michel Goossens, INSERM 94010,
Creteil, France). A clone expressing the rat GH receptor (11) was
likewise generated in FDC-P1 cells. BaF-B03 cells (a gift from Dr. Tom
Gonda (Hanson Institute, Adelaide, Australia)), were likewise co-trans-
fected with p-Neo expression vector and the rGHR-pECE, hGHR-pECE,
or Q2166 R2176 del218 hGHR-pECE (loop delete (7), constructed by
Altered Sites, Promega) construct by electroporation as described for
FDC-P1 cells. After G418 selection (0.3 mg/ml for FDC-P1, 1.2 mg/ml for
BaF-B03 cells) and cloning by limiting dilution, binding assays utilizing
125I-hGH were performed on individual clones to detect positive GHR-
expressing lines. Further characterization was performed on each clone
to determine receptor number and affinity as described for FDC-P1 cells
above (10). All cell lines were maintained in phenol-free RPMI 1640
with 5% FCS, 1 mg/ml gentamicin at 37 °C, and 5% CO2 with either
recombinant hGH (Bresatec Ltd., Adelaide, Australia) at 40 ng/ml or
recombinant IL-3 (a generous gift of Dr. Andrew Hapel at the John
Curtin School of Medical Research, Canberra, Australia) at 100
units/ml.
Preparation of mAbs—mAbs 1, 5, 7, 43, 44, and 263 have been
extensively characterized (12–14) and were supplied by Agen Ltd.
(Acacia Ridge, Brisbane, Australia). mAb 1C9 was an anti-idiotype
mAb, raised against a rabbit anti-hGH Fab (15), while all other anti-
human receptor mAbs used in this study were raised against full-length
recombinant nonglycosylated hGH receptor (residues 1–246) but known
to cross-react with native hGH-binding protein (16). Anti-hGH mAbs 20
and 21 (17) were a generous gift of Dr. Jim Wells (Genentech, S. San
Francisco, CA). All mAbs were Protein A-purified in the manner de-
scribed in Ref. 18 and underwent extensive dialysis against PBS and
filter sterilization before use. Prior to cell proliferation and binding
assays, samples of each mAb were run on a 12.5% SDS-polyacrylamide
gel (19) under both reduced and nonreduced conditions to ensure their
integrity.
Precipitation and Inhibition Assays with mAbs—As a means to de-
termine that the mAbs used were able to recognize the GHR, precipi-
tation assays were performed as described previously (12–14). Rabbit
liver cytosol was prepared as described in Ref. 14, while recombinant
human GHBP was a gift from Dr. Steve Spencer (Genentech).
Inhibition assays were performed with 125I-bGH (for somatotrophic
receptor) in the manner described in Ref. 12 with male rabbit liver
microsomes prepared by the protocol described in Ref. 14. Inhibition
assays with the chimeric receptor- and hGHR-expressing cells were
performed with 125I-hGH in the same manner, except physiological
binding buffer supplemented with 2 mM MgCl2 (8) was used. Cells were
washed three times with an equal volume of PBS and resuspended in
physiological buffer before 100-ml aliquots containing approximately
3 3 107 cells/ml were added to each assay tube. Assays were terminated
by the addition of 2 ml of ice-cold physiological buffer (18) followed by
centrifugation at 1600 3 g, removal of the supernatant, and counting of
the pellet in an LKB 1274 auto-g-counter (LKB-Producter AB, Bromma,
Sweden).
To determine if the epitope for mAb 263 was affected by the F9–G9
loop mutated hGHR, Scatchard analysis was performed with 125I-mAb
263 as described above in the characterization of the GHR-expressing
clones, with 125I labeling of mAb 263 as described by Gobius et al. (18).
Cell Proliferation Assays—Cell proliferation was assessed using the
MTT assay (20) as described in Ref. 10 except that a final concentration
of FCS of 0.5% was used to decrease the background resulting from
bovine GH in the FCS. The ability of the mAbs to stimulate cell prolif-
eration was tested in the presence or absence of GH, as follows. To 50 ml
of PBS-washed cells (8 3 105 cells/ml for FDC-P1 cells and 4 3 105
cells/ml for BaF-B03 cells) was added 50 ml of mAb followed 30 min later
by 50 ml of media either devoid of or containing GH. A submaximal
concentration of GH (25 ng/ml of porcine GH for rabbit GHR-expressing
FDC-P1 cells, 2.5 ng/ml hGH for human GHR- and the chimeric recep-
tor-expressing FDC-P1 cells, and 0.3 ng/ml of hGH for GHR-expressing
BaF-B03 cells) was used in assays to determine the effects of mAbs on
the GH response. This latter procedure was utilized in case of synergy
with GH to increase the rate of GHz(GHR)2 complex formation. For cell
proliferation assays utilizing anti-mouse second Ab (anti-(H 1 L) affin-
ity-purified; The Binding Site, Birmingham, UK), this was added 15
min after the addition of the primary mAb. After a 24-h incubation, 50
ml of 3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium bromide at a
concentration of 4 mg/ml was added to each well, and after a further
incubation for 3 to 4 h in the dark, cells were lysed with 120 ml of
isopropyl alcohol. The absorbance of the oxidized dye was measured on
a model 450 microplate reader (Bio-Rad Laboratories Pty Ltd, North
Ryde, Australia) at 595 nM.
Assays involving the anti-hGH mAbs 20 and 21 (17) were performed
with BaF-B03 hGHRB2B2 cells at a density of 2 3 104 cells/well and
hGH at a final concentration of 0.3 ng/ml. Assays were performed in two
ways: first, by adding hGH to the BaF-B03 hGHRB2B2 cells, followed
by increasing concentrations of mAbs 20 and 21 into replicate wells, and
second, by adding either 5 or 50 nM mAbs 20 and 21, followed 15 min
later by increasing concentrations of anti-mouse second Ab into repli-
cate wells. Cells were processed as described above for proliferation
assays.
c-fos Promoter Assays—Promoter activation assays were performed
on CHO-K1 cells in the same manner as described in Refs. 21 and 22)
using the c-fos 396del219–81 construct (21), except that assay precision
was improved by co-transfecting a b-galactosidase construct to normal-
ize for transfection efficiency, and the chosen GHR mAbs were substi-
tuted for hGH.
Acute Phase Response Element (APRE) Electrophoretic Mobility Shift
Assay (EMSA)—FDC-P1 cells expressing human and rabbit GHRs were
grown in RPMI 1640, 10% FCS, and 100 ng/ml hGH. Cells were washed
twice with PBS and resuspended in RPMI 1640 supplemented with
0.8% FCS at a concentration of 1.5 3 107 cells/ml. 500-ml aliquots of
cells were dispensed into 24-well plates, incubated for 24 h, and then
treated with either GH or mAbs at a final concentration of 4.5 or 100
nM, respectively. Following a 15-min exposure to either GH or mAbs,
crude nuclear extracts were prepared using the protocol described in
Ref. 23.
Each EMSA binding mixture (22 ml) contained 3 ml of nuclear extract
(approximately 5 mg of protein), 4 mg of bovine serum albumin, 2 mg of
poly(dI-dC), 0.5 mg of labeled oligonucleotide in 12 mM HEPES (pH 7.9),
12% glycerol, 0.12 mM EDTA, 38 mM KCl, 0.9 mM MgCl2, 0.6 mM
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dithiothreitol, 0.3 mM pefabloc (Boehringer Mannheim, Castle Hill,
Australia) and 1.2 mg/ml aprotinin and leupeptin. Samples were incu-
bated on ice for 1 h and electrophoresed on 6% polyacrylamide, 1 3 TBE
(Tris borate/EDTA) gels. The double-stranded oligonucleotide probe
used in EMSA, APREv (59-GAT CCT TCC GGG AAT TCC TA), con-
tained a high affinity binding site for STAT3 (24). Complementary
strands of this probe were synthesized on a Milligen/Biosearch 7500
DNA synthesizer, annealed, 59-end-labeled with T4 polynucleotide ki-
nase (Pharmacia), and purified on a 10% polyacrylamide gel.
RESULTS
Receptor Expression in Clonal Lines—FDC-P1 cells contain-
ing the full-length hGHR (10), rabbit GHR (rbGHR) (8), and
chimeric hGHR/mG-CSF receptor (4) have been previously de-
scribed. The rabbit and human GHR-containing FDC-P1 cells
have been shown to possess 212 6 12 and 372 6 82 receptors/
cell (mean 6 S.E.), respectively, when grown in 40 ng/ml hGH.
These values are considerably less than that described for the
hGHR/mG-CSF containing cells (1000 6 300 receptors/cell)
maintained in GH-free medium (4). Since the number of sur-
face-expressed receptors will influence the likelihood of recep-
tor dimerization by the cross-linking mAbs, FDC-P1 cells ex-
pressing GHRs were likewise grown in IL-3 support medium
without GH to limit receptor down-regulation. Under these
conditions, the receptor expression was shown to increase to
2102 6 186 receptors/cell and 2393 6 310 receptors/cell for the
hGHR- and rbGHR-containing FDC-P1 lines, respectively.
Transfection of BaF-B03 cells with hGHR and rbGHR re-
sulted in clones expressing between 500 and 15000 receptors/
cell in IL-3 support medium. Because we observed that the
magnitude of the proliferative response was proportional to the
number of expressed receptors (data not shown), we performed
proliferation assays on clones expressing approximately the
same number of receptors; BaF-B03-hGHRB2B2 has 7419 6
777 receptors/cell with an affinity of 2.5 6 0.2 3 109 M21, and
BaF-B03-rbGHR has 7285 6 618 receptors/cell with an affinity
of 6.0 6 0.6 3 109 M21. The BaF-B03 clone expressing the loop
deleted hGHR has 7540 6 1190 receptors/cell with an affinity
of 1.7 6 0.4 3 109 M21.
Precipitation and Inhibition Assays with mAbs—To confirm
that the purified mAbs used were active against the human
and rabbit GHRs, we determined their ability to precipitate the
rabbit and human GHBP and to inhibit the binding of 125I-bGH
to rabbit liver microsomes and 125I-hGH to the hGHR and
chimeric (hGHR/mG-CSF) receptor-expressing cells (Table I).
Two of the mAbs, 7 and 44, were unable to precipitate the
125I-hGHzhuman GHBP complex, although they did react with
the rabbit GHR. This result with mAb 7 confirms earlier find-
ings that mAb 7 does not recognize the hGHR (25). All other
mAbs recognized the hGHR; however, mAbs 1, 5, 9H12, and
10B8 did not compete with hGH for the GHR binding site. mAb
263 was the only mAb that showed intermediate inhibition of
125I-hGH binding, approximately 50% at a concentration of 100
nM (Table I). This intermediate level of inhibition occurs de-
spite mAb 263 having a high titer for the GHR (25). Against the
chimeric receptor, mAbs 43 and 263 are partly effective at
displacing hGH binding (Table I).
Against the rbGHR, mAbs 5 and 44 are only partial inhibi-
tors of 125I-bGH binding to the rabbit GHR. These mAbs and
mAb 1 have previously been shown to be poor inhibitors of
125-hGH binding to the rbGHR (12–14). We have recently
shown (46) that high affinity binding of non-primate GHs to the
GHR is dependent on receptor dimerization, so the loss in
binding of 125I-bGH observed in the presence of these mAbs
may be a result of the inhibition of trimeric complex formation
rather than direct competition for the GH binding domain. This
is the case for mAb 5 (2).
Cell Proliferation Assays—Because of the large difference in
receptor expression observed between FDC-P1 cells grown in
either GH or IL-3 (as reported above), the ability of the mAbs to
stimulate cell proliferation was tested with cells prepared un-
der both conditions. With the mAbs tested, no significant dif-
ferences were observed. We have only included in Table I the
results obtained with the cells grown in the absence of GH (100
units/ml IL-3), since these cells express the greater receptor
number.
Cell Proliferation Assays Performed on FDC-P1 Cells Ex-
pressing the Chimeric hGHR/mG-CSF Receptor—FDC-P1 cells
containing the chimeric hGHR/mG-CSF receptor were found to
proliferate in the presence of a number of the mAbs (examples
shown in Fig. 1A). mAb 263 was able to induce the largest
response in these cells, achieving a similar maximum response
to that obtained with GH alone. When the mAbs were assayed
in the presence of a half-maximal dose of GH, a number of
TABLE I
Binding and biological characterization of anti-hGHR mAbs
Results are the mean of three determinations with S.E. indicated. The concentration of mAb used was that which gave a maximal response
(between 10 and 300 nM).
mAb Immunogen
Competes with hGH binding
domain of
Maximal GH-induced proliferation
in FDC-P1 cells expressing
Inhibition of proliferation in
FDC-P1 cells expressing
G-CSF/hGHR hGHR rGHR G-CSF/hGHR hGHR rGHR G-CSF/hGHR hGHR rGHR
% %
1 Rabbit GHR No No Yes 0 0 0 100 40a 100
5 Rabbit GHR No No —b 0 0 0 100 40 100
7 Rabbit GHR nxrc nxr Yes nxr 0 0 nxr nxr 100
43 Rabbit GHR —d —d Yes 56.3 6 6.7 0 0 50.6 6 4.3 0 100
44 Rabbit GHR nxr nxr —b nxr 0 0 nxr nxr 37.6 6 2.6
263 Rat/rabbit GHR —d —d —d 94.3 6 5.8 0 0 0 0 10.2 6 1.7
IC9 Anti-Id hGHR NDe Yes ND 3.8 6 0.5 0 0 43.0 6 12 28.3 6 2.0a 0
2C8 HumanGHR ND Yes ND 27.7 6 4.8 0 0 88.0 6 10.0 100 100
3D2 HumanGHR ND Yes ND 21.8 6 4.6 0 0 89.5 6 3.7 100 100
5C6 HumanGHR ND Yes ND 46.6 6 2.8 0 0 59.0 6 0 91.1 6 1.0 93.5 6 6.6
6C3 HumanGHR ND Yes ND 15.1 6 1.0 0 0 83.5 6 2.5 100 100
6F5 HumanGHR ND Yes nxr 8.5 6 0.8 0 0 100 100 nxr
9H12 HumanGHR ND No ND 44.6 6 2.3 0 0 0 0 58.0 6 2.0
10B8 HumanGHR ND No ND 40.3 6 2.7 0 0 21.1 6 4.0 0 100
a Inhibition has not plateaued by 100 nM mAb.
b Shows some inhibition (,50%) of 125I-GH binding, which may be due to inhibition of GHR dimer formation.
c nxr, no cross-reactivity of mAb with receptor.
d Inhibits GH binding by 50% or less.
e ND, not determined.
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mAbs were shown to inhibit the GH-induced proliferation (Ta-
ble I). In the case of mAbs 1C9, 6C3, 6F5, 1, and 5 this was
associated with weak or nil proliferative activity, respectively,
when tested without GH present. On the other hand, mAbs 43,
2C8, 3D2, and 5C6 were found to inhibit the GH-stimulated
proliferative response, but as the concentration of the mAb was
increased, an agonist response was observed, resulting in a
U-shaped growth-response curve (Fig. 1B).
The maximum proliferative response obtained with the chi-
meric receptor could be further enhanced by the addition of
anti-mouse second antibody. An example is depicted in Fig. 2,
where the level of mAb 43 stimulation is increased from 65 to
100% of the GH response when co-incubated with 50 nM second
Ab at 10 nM mAb 43 and from 30 to 70% of the GH maximum
at 0.5 nM mAb 43 and 5 nM second mAb.
Cell Proliferation Assays Performed on FDC-P1 Cells Ex-
pressing rbGHR, hGHR, and Rat GHR—In contrast to the
results obtained with the FDC-P1 cells stably expressing chi-
meric receptor, FDC-P1 cells stably expressing either the full-
length hGHR or rbGHR did not yield a proliferative response
upon the addition of any of the mAbs (Table I), either by
themselves or in the presence of a secondary anti-mouse Ab
(results not shown). In fact, a number of the mAbs were inhib-
itory to the GH-induced cell proliferation. The strongest inhib-
itors for the hGHR-expressing cells were 2C8, 3D2, 5C6, 6C3,
and 6F5, while for the rbGHR cells, these same mAbs (except-
ing 6F5) as well as mAbs 1, 5, 7, and 43 were strong inhibitors
of cell proliferation (Table I). In a separate study,2 the response
of FDC-P1 cells stably transfected with rat GHR was exam-
ined, and it was found that mAbs 263, 43, 44, and 5 up to 100
nM were unable to elicit a proliferative response, while the
hGH-positive control gave a 3.3-fold stimulation.
Cell Proliferation Assays Performed on BaF-B03 Cells Ex-
pressing rbGHR, hGHR, and the Loop hGHR Mutant—Because
we observed that the BaF-B03 cells expressing the GHR were
10 times more sensitive to GH than FDC-P1 cells expressing
the same GHR constructs (the ED50 for hGHRFDC-P1 and
hGHRBaF-B03 cells is 2.45 6 0.32 and 0.25 6 0.02 ng/ml,
respectively), we tested our panel of mAbs for their ability to
induce a proliferative response in BaF-B03 stable lines. Only
two of the mAbs (mAb 263 and anti-Id IC9) were able to elicit
a biological response from the hGHR, although this was only a
small fraction (approximately 5%) of that with GH alone (Table
II). Even in the presence of an anti-mouse second Ab, again
only mAbs 263 and IC9 were able to stimulate a proliferative
response in the hGHR-expressing BaF-B03 cells (Table II and
Fig. 3). This response, however, was considerably less than that
seen with GH alone.
With the rGHR-expressing cells, mAb 263 was able to give a
stimulatory response that was 23% of that achieved with GH,
while no response was observed with anti-hGHR mAb 1C9
(Table II). None of the other mAbs tested were able to induce a
proliferative response in either the absence or presence of the
secondary Ab.
In contrast to the stimulation seen with mAb 263 against the
intact hGHR-expressing BaF-B03 cells, mAb 263 elicited only a
weak proliferative response with the BaF-B03 cell line express-
ing the F9–G9 loop delete mutant hGHR (Fig. 4 and Table II).
This was seen although both cell lines displayed the same
number of receptors. With this same receptor mutant line, hGH
was likewise unable to elicit a maximum response of the order
of that seen with wild type hGHR-expressing cells (Fig. 4).
Cell Proliferation Assays Performed on BaF-B03 Cells Ex-
pressing hGHR in the Presence of Anti-hGH mAbs 20 and
21—Anti-hGH mAbs 20 and 21 are directed to Ile36 and Pro37
(mAb 20 and 21) and Leu156 (mAb 21) (17), hence away from
receptor binding sites 1 or 2 (3) and so should be able to form a
quaternary complex. Simultaneous binding of both valencies
2 W. Baumbach, unpublished results.
FIG. 1. Proliferative response of chimeric hGHR/G-CSF-ex-
pressing FDC-P1 cells (HC-2 cells) to the presence of mAbs 2C8,
6C3, 7, 43, and 263 only (A) and mAbs 2C8, 3D2, 5C6, and 43 in
combination with hGH at a final concentration of 2.5 ng/ml (B).
Prior to the addition of mAbs, cells were washed in PBS and resus-
pended in growth media devoid of growth factors (A) or in media
containing hGH (B), as described under “Materials and Methods.” Each
point is the mean of a quadruplicate determination with S.E. indicated,
with the assay having been performed three times. Cell growth was
calculated as a percentage of the maximum GH response (typically 0.5
absorbance units at 100 ng/ml), determined in parallel.
FIG. 2. Proliferative response of chimeric hGHR/G-CSF ex-
pressing FDC-P1 cells (HC-2 cells) to increasing concentrations
of mouse second Ab in the presence of mAb 43, either at 0.5 or 10
nM. Assays were performed in the manner described under “Materials
and Methods,” with each point being the mean of a quadruplicate
determinations with S.E. indicated and with the assay run on three
separate occasions.
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would result in side by side apposition of two GHz(receptor)2
complexes and, if receptor aggregation is a factor in signaling,
should result in an enhanced proliferative response. Accord-
ingly, mAbs 20 and 21 were co-incubated with BaF-B03 cells
expressing hGHR and a half-maximal concentration of hGH. It
was found that neither of these mAbs was able to increase the
hGH proliferative response from these cells when used either
alone (Fig. 5) or in the presence of a second anti-mouse anti-
body to further increase receptor aggregation (results not
shown).
c-fos Promoter Assays—None of the mAbs tested in the GHR/
c-fos co-transfection assay in Chinese hamster ovary cells were
able to induce a significant luciferase reporter response with
either the human or rabbit GHR at 100 nM mAb (examples in
Fig. 6). In addition to the assays shown in Fig. 6, a concentra-
tion range of 0.1–100 nM of mAbs 43 and 263 were tested
against the human GHR (as in Fig. 6B). In all cases, the mAbs
were unable to induce significant c-fos promoter activity, al-
though the positive control hGH was able to give 2.4-fold
stimulation.
APRE Gel Shift Assay—Using EMSA, none of the mAbs were
able to induce observable induction of binding to an APRE
probe with nuclear extracts from FDC-P1 cells expressing ei-
ther the rabbit GHR (Fig. 7A) or human GHR (Fig. 7B). In
contrast, hGH was able to induce APRE binding in both cell
lines.
DISCUSSION
The ability of receptor antibodies to mimic a hormone re-
sponse is not a new observation. The earliest reports of this
phenomenon were with polyclonal antibodies against the insu-
lin and thyrotropin receptors (26, 27). More recent examples
include activation of human B lymphocytes via mAbs directed
against CD40 (28), stimulation of cell proliferation with a mAb
raised against the IL-3 receptor (29), and activation of receptor
tyrosine kinase activity with a mAb directed against the epi-
dermal growth factor (30). It is generally believed that bivalent
antibodies activate these receptors by inducing dimerization,
although in the case of the insulin receptor (which exists as a
preassociated dimer (31)), activation as in the example shown
by Xiong et al. (32) is presumably a consequence of an induced
conformational change.
With the GHR, it was shown by Fuh and colleagues (4) that
intact mAbs (but not Fab fragments) directed against the ex-
tracellular domain of the GHR are capable of stimulating cell
proliferation in FDC-P1 cells containing the chimeric hGHR/
mG-CSF receptor. This result indicated that signal transduc-
TABLE II
Proliferative responses of mAbs 263 and 1C9 in the presence and
absence of a second anti-mouse Fab with BaF-B03 lines
The concentration of mAbs 263 and 1C9 was 100 nM (hGHR B2B2
cells) or 300 nM (rabbit GHR cells) when used without second antibody.
Where second (anti-mouse) antibody was added, mAb 263 was used at
50 nM and 1C9 at 100 nM (hGHR B2B2 cells), or 300 nM mAb 263 was
used (rabbit GHR cells) with, in all cases, 100 nM second antibody.
Results are the mean of three determinations with S.E. indicated.
mAb
Maximal GH-induced proliferation in BaF-B03 cells
expressing
rGHR hGHR hGHR loop delete hGHR
%
1C9 0 6.4 6 2.4 NDa
1C9 plus 2nd Ab 0 9.5 6 2.9 ND
263 23.0 6 4.5 5.4 6 1.7 4.8 6 0.5
263 plus 2nd Ab 19.6 6 2.3 28.2 6 4.5 6.9 6 0.6
a ND, not determined.
FIG. 3. Proliferative response of hGHR-expressing BaF-B03
cells in the presence of increasing concentrations of a second
anti-mouse Ab in the presence of 100 nM mAb 263. The assay
procedure is described under “Materials and Methods,” and each point
is the mean of a quadruplicate determinations with S.E. indicated,
repeated twice.
FIG. 4. Proliferative response of BaF-B03 cells expressing ei-
ther the full-length hGHR or the F*–G* loop mutated hGHR to
500 units/ml IL-3, 100 ng/ml hGH, 50 nM mAb 263, or 100 nM mAb
263 co-incubated with 50 nM of anti-mouse Fab. Assays were
performed in the manner described under “Materials and Methods.”
Each column is the mean of a quadruplicate determination with S.E.
indicated. Since BaF-B03 cells are IL-3-dependent, the proliferative
responses obtained from the two different GHR cell lines were normal-
ized by expressing the treatment responses as a percentage of the
maximum IL-3 response (500 units/ml). Results shown are the mean 6
S.E. of quadruplicate determinations in triplicate. wt, wild type.
FIG. 5. Proliferative response of BaF-B03 cells expressing
hGHR when assayed in the presence of a half-maximal value of
hGH (0.3 ng/ml final concentration) but increasing concentra-
tions of anti-hGH mAbs 20 and 21. The assay procedure is described
under “Materials and Methods,” while each point depicted is the mean
of a quadruplicate determination with S.E. indicated. Values are ex-
pressed as a percentage of the maximum GH response that was ob-
tained at a final hGH concentration of 100 ng/ml.
Growth Hormone Receptor Activation 5311
 at UQ Library on October 19, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
tion through the GHR could be achieved by formation of a GHR
dimer, independent of GH. Support for this view came from
studies with the prolactin receptor, which is similar to the GHR
in both homology (33, 34) and kinetics of binding (35). mAbs to
this receptor were found to induce a mitogenic response in
Nb2–11C cells, shown by addition of mAbs directed to the
extracellular domain (36, 37). Moreover, Fab fragments of the
same mAbs were unable to induce a biological response in these
studies (36). However, a number of prolactin receptor mAbs
were unable to trigger signal transduction (38), and even the
mAbs most effective at stimulating proliferation are in excess
of 100-fold less potent than prolactin on a molar basis (37).
In order for a mAb to initiate a response through the GHR,
the binding epitopes on the dimerized receptor must have a
juxtaposed and spatial separation that is complimentary to the
distance between the Fab domains in the intact mAb. In addi-
tion, the Fab binding sites must have unimpeded access to
these epitopes on the receptor. Since the chimeric mG-CSF/
hGH receptor has been shown to be activated by intact mAbs
raised against the extracellular domain of the GHR, this cell
line is appropriate for assessing which of our panel of mAbs are
spatially and sterically most likely to correctly dimerize two
full-length GHRs and thus to potentially induce a biological
response.
The HC-2 FDC-P1 cells, expressing the chimeric hGHR/mG-
CSF receptor, were shown to be responsive to a number of
mAbs raised against the GHR (Table I and Fig. 1). Of all of the
mAbs tested, mAb 263 was the most efficient at inducing a
proliferative response in these cells, since the maximal re-
sponse was nearly equivalent to that induced by GH alone
(Table I). Four of the mAbs, 43, 5C6, 9H12b, and 10B8 gave a
40% or greater response, while three others, 2C8, 3D2, and 6C3
gave between a 15 and 30% response (Table I). It is notable that
there was no correlation between ability to stimulate cell pro-
liferation and competition for the GH binding site on the
receptor.
In addition to testing the proliferative capability of these
mAbs with the chimeric receptor, we examined each for its
ability to inhibit the GH-induced response with this cell line.
mAbs 1, 5, and 6F5 were the most potent inhibitors, with mAbs
3D2, 2C8, 6C3, 5C6, 43, 1C9, and 10B8 showing decreasing
degrees of inhibitory ability (Table I). From the epitope map-
ping (Table I), it is not surprising that mAbs 43, 1C9, 2C8, 3D2,
5C6, 6C3, and 6F5 are inhibitory, since they compete with hGH
for the GH binding domain. The inability of many of these
mAbs to fully abolish the GH-induced signal is most likely due
to the stimulatory ability of these mAbs at high concentrations.
In support of this theory, a U-shaped dose-response curve was
observed with four of these mAbs, 43, 5C6, 3D2, and 2C8 (Fig.
1B). We suggest that these antibodies inhibit hormone stimu-
lation at low concentrations because they block dimerization by
hormone, whereas at higher concentrations they bind for a
sufficient period to enable the use of both valencies to dimerize
and activate the receptor. The inhibitory ability of mAb 5, and
possibly mAbs 1 and 6F5, is most likely a result of their steri-
cally impeding dimerization of two GHRs by binding to the
GHR dimerization domain or inducing an unproductive confor-
mation for signaling. mAb 5 has previously been shown to
inhibit dimerization of the GHBP in solution (2), and the
D152H mutation in the dimerization domain of the hGHR has
been shown to affect the binding epitope of mAb 5 (39). From
these results, it is clear that at least eight of the mAbs are good
candidates for inducing a proliferative response in cells con-
FIG. 6. c-fos promoter transactivation assay showing lack of
induction by mAbs. This assay was undertaken with rbGHR-express-
ing FDC-P1 cells using the designated mAbs at 100 nM (A) or with
increasing concentrations of mAb 263 or 43 (B) as described under
“Materials and Methods.” Results shown are the mean 6 S.E. of quad-
ruplicate luciferase assays for each point, with the assay repeated
twice.
FIG. 7. STAT3 gel shift (EMSA) showing lack of induction by
mAbs. Nuclear extracts from rbGHR- (A) or hGHR- (B) expressing
FDC-P1 lines exposed to indicated mAbs or hGH for 15 min were run
with an end-labeled APRE probe (see “Materials and Methods”). A
similarly labeled Oct-1 probe was used as a loading control (23).
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taining the full-length GHR, assuming similar steric
constraints.
With the FDC-P1 cells containing either the full-length hu-
man or rabbit GHRs, none of our panel of 14 mAbs tested were
able to stimulate cell proliferation (Table I). In addition, mAbs
5, 43, 44, and 263 were unable to induce a proliferative re-
sponse in FDC-P1 cells containing the rat GHR receptors (re-
sults not shown). A number of the mAbs were, however, potent
inhibitors of the GH-induced proliferative response (Table I).
This was expected based on their ability to compete with GH
for the GHR binding domain, although in the case of mAb 5
(and possibly mAbs 1 and 6F5) this is due to its ability to
inhibit dimerization. Consistent with these results, we were
unable to show a STAT3/APRE activation when a number of
our mAbs were tested (Fig. 7). Further supporting the inability
of these mAbs to signal, we found that they were also unable to
induce c-fos promoter activation in Chinese hamster ovary cells
co-transfected with the full-length GHR (Fig. 6).
In the course of our studies with the GHR, we have found
that BaF-B03 cells transfected with the GHR are as much as 10
times more sensitive to GH than FDC-P1 cells expressing the
same GHR constructs. Accordingly, we tested our panel of
mAbs against these GHR-expressing BaF-B03 cells. In contrast
to the above results obtained with the FDC-P1 cells, we were
able to show that two of the mAbs, 1C9 and 263, are weak
activators of cell proliferation in the hGHR-expressing BaF-
B03 cells (4.8 6 0.5 and 5.4 6 1.7% of the GH response,
respectively), while in the rbGHR-expressing BaF-B03 cells,
mAb 263 was able to elicit 23.0 6 4.5% of the maximum GH
response (Table II). These results suggest that proliferative
signaling pathways are better coupled in BaF-B03 cells than in
FDC-P1 cells.
Although the affinity of mAb 263 for the GHR is similar to
that measured with GH (18), it is possible that the magnitude
of the mAb 263 signal may be limited by the instability of the
mAbz(GHR)2 complex. Because it has been shown that a second
antibody in combination with Fab fragments can be used to
promote prolactin receptor signaling (36), we have utilized a
second anti-mouse antibody to achieve the same effect.
Through use of the chimeric cell line, we were able to show that
we could indeed increase the sensitivity and maximum re-
sponse of the cells to mAb 43 through increasing the concen-
tration of the second antibody (Fig. 2). At high secondary:
primary antibody ratios, a decrease in proliferative activity
was observed, presumably as a result of the steric hindrance of
binding of the primary mAb to the receptor.
In the presence of the second antibody, mAbs 1C9 and 263
were still the only mAbs that were able to produce a prolifer-
ative response in the human GHR BaF-B03 line (Figs. 3 and 4
and Table II). For mAb 263, second antibody addition resulted
in a response 4-fold greater than achievable with mAb 263
alone, indicating that the secondary mAb is either stabilizing
the mAbz(GHR)2 complexes or enhancing GHR oligomerization.
Despite the increase in proliferative activity observed with the
secondary antibody, the maximum response observed in the
hGHR-expressing BaF-B03 cells was still less than one-third of
that obtained with GH alone. Indeed, with the rbGHR-BaF-
B03 cells, no further enhancement could be achieved, probably
because mAb 263 binds with greater than 10-fold higher affin-
ity to the rabbit receptor (14, 25).
In the above experiments with mAb 263 in combination with
a second anti-mouse antibody, we could not determine if the
greater cell proliferation response we obtained was simply a
result of dimer stabilization or due to aggregation of dimerized
GHR complexes in a manner that increases the efficiency of
signaling (for example by concentrating the number of signal-
ing units (e.g. JAK2) in a predetermined region of the cell). To
address this issue, we utilized mAbs 20 and 21 to induce
signaling unit aggregation, because these mAbs have been
shown through extensive epitope mapping studies to bind to
the nonreceptor interactive region of the hormone, located at
the side of the GHz(receptor)2 complex (17). Neither mAb 20 or
21 increased the proliferative response (Fig. 5), and in fact mAb
20 was inhibitory, possibly due to some steric hindrance of GH
binding to the GHR. The addition of anti-mouse second anti-
body to facilitate further aggregation also did not increase the
proliferative response. These results, especially that obtained
with mAb 21, suggest that aggregation of signaling units does
not increase signaling and indicate that the increased prolifer-
ation observed through use of the second anti-mouse antibody
in combination with the anti-GHR mAbs is a result of stabili-
zation of the dimerized GHR complex.
It is clear from the above results that although it is possible
for mAbs raised against the GHR to elicit a proliferation signal
with the full-length GHR, this ability is weak and limited to
only two of the mAbs we have tested. This limitation exists
despite the fact that a number of the mAbs have receptor
binding epitopes that are sterically and spatially suited to
dimerizing two GHRs that are linked to the fibronectin do-
mains of G-CSF receptor (Table I and Fig. 1). We conclude that
the chimeric receptor is not a good model for assessing GH
receptor coupling that results from either mAb or GH binding.
Indeed, it is clear upon comparing results obtained with mAbs
tested against the hGHR/G-CSF and full-length hGHR-ex-
pressing FDC-P1 cells that significant differences exist be-
tween these receptors. For example, mAb 43 was found to
inhibit the GH-induced response in the G-CSF/hGHR FDC-P1
cells, but it is unable to do so in the hGHR FDC-P1 cells. Why
is the chimeric receptor more responsive to mAb agonists?
Apart from the obvious difference between the GH and G-CSF
cytoplasmic domains, it could be that the hGHR/G-CSF recep-
tor exists in a partially activated form or in a form that is more
easily able to undergo the transition to the activated receptor.
For example, the additional extracellular fibronectin domains
in the chimeric receptor could favor facile dimerization. It
should, however, be noted that the ability of the antibodies to
activate the chimeric receptor is still 100-fold less than hor-
mone on a molar basis, although their affinity for the receptor
is similar (12–16, 18).
From the results obtained with the full-length GHR-express-
ing BaF-B03 cells and mAbs 1C9 and 263, it is apparent that
although these mAbs have the ability to stimulate a prolifera-
tive response, the magnitude of this response is significantly
lower than that observed with GH alone even with the help of
a secondary Ab. The inability of mAbs to evoke a response with
a full-length receptor equivalent to that obtained with the
ligand alone is also seen with the prolactin receptor (36, 37) and
erythropoietin receptor (40). It would therefore seem that al-
though mAbs are able to induce dimerization of receptors, the
efficiency of signal activation is reduced. This could be either a
result of critical steric requirements for alignment of dimeriza-
tion domain residues in domain 2 (5) or a requirement for a key
conformational change that allows efficient coupling to second
messenger pathways.
What is the evidence that a conformational change plays a
role in signaling through the single transmembrane spanning
segment? First, in the crystal structure, the angle between
domains 1 and 2 differs between receptor 1 and 2 by 9° (3).
Second, JAK2 binding to the GHR is weak until hormone binds
(41),3 suggesting that a hormone-induced conformational
3 C. Carter-Su, personal communication.
Growth Hormone Receptor Activation 5313
 at UQ Library on October 19, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
change increases the availability of box 1. Third, Mellado et al.
(42) have recently presented evidence based on an agonist GHR
mAb directed to the link (hinge) region between domains 1 and
2 that this mAb induces a conformational change required for
GHR signaling. Fourth, hormone binding loops exist within the
crystal structure of the GHR subunits 1 and 2, which differ in
conformation between receptor 1 and 2 as a result of hormone-
induced assembly of the signaling complex (residues 101–106,
163–168 (3), and 218–221 (8)). The b-loop connecting the F9–G9
strands in domain 2 (residues 216–220) is adjacent to the
WSXWS box equivalent in the GHR (YGEFS) and the link
(hinge) region and is also the last turn prior to insertion into
the membrane. We have proposed that a GH-induced confor-
mational change in this loop is necessary for proliferative sig-
naling, since GH mutants interacting with this loop appear to
act as partial antagonists for proliferation (8). Moreover, re-
moval of residues on this b-loop strikingly reduces proliferative
signaling in FDC-P1 cells expressing these mutant receptors
(7). Accordingly, hormone-induced conformational changes in
this region appear to be components of the mitogenic signal.
In support of the importance of this F9–G9 loop in signaling,
we have shown here that, like GH itself, mAb 263 is unable to
induce a wild type receptor response in BaF-B03 cells express-
ing the loop delete receptor (Table II and Fig. 4). Since this cell
line expresses the same number of receptors as the wild type
control cell line that responds to mAb 263 and since we have
shown that the introduced mutation does not adversely affect
binding of mAb 263 to this receptor (indeed, binding affinity is
increased 2-fold), we conclude that this loop is also a necessary
component in mAb 263 signaling. This would suggest that mAb
263 is not only dimerizing two GHRs but also induces the same
conformational changes required for signal transduction as GH
itself.
This study does not rule out the possibility that fully effective
mAb agonists for the GH receptor exist or can be engineered.
Indeed, Wang et al. (43) have reported a mAb to the GHR that
is able to stimulate growth in the hypophysectomized rat. A
similar argument applies to small GH mimetics. Indeed, pep-
tide mimetics have been constructed that are able to both
dimerize and activate the homologous erythropoietin receptor
(44). Of note, the crystal structure of the peptide mimic com-
plexed with two erythropoietin receptors reveals that the F9–G9
loop, which we have shown to be important in GHR signaling
(7), appears to be one of the major peptide binding epitopes on
the receptor (44).
We conclude from this study that particular mAbs against
the GHR are able to activate signal transduction through the
full-length human and rabbit GHRs, although, in the case of
the two mAbs (one an anti-idiotype hGH mimetic) identified
here, the efficiency of signaling is significantly reduced com-
pared with that obtained with GH alone. This could be a result
of particular steric constraints for the membrane-bound recep-
tor or a requirement for a specific conformational change. Since
our data indicate that the receptor epitope involved in binding
of the most effective agonist mAb is involved in a conforma-
tional change, we propose that in addition to dimerization,
specific conformational changes within the receptor are re-
quired for effective signaling.
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